| Literature DB >> 28941241 |
Yeri Alice Rim1,2, Narae Park1,2, Yoojun Nam1,2, Dong-Sik Ham3, Ji-Won Kim3, Hye-Yeong Ha4, Ji-Won Jung4, Seung Min Jung5, In Cheol Baek6, Su-Yeon Kim6, Tai-Gyu Kim6, Jihwan Song7, Jennifer Lee1,2, Sung-Hwan Park2, Nak-Gyun Chung8, Kun-Ho Yoon3, Ji Hyeon Ju1,2.
Abstract
Induced pluripotent stem cells (iPSCs) can be generated by introducing several factors into mature somatic cells. Banking of iPSCs can lead to wider application for treatment and research. In an economical view, it is important to store cells that can cover a high percentage of the population. Therefore, the use of homozygous human leukocyte antigen-iPSCs (HLA-iPSCs) is thought as a potential candidate for effective iPSC banking system for further clinical use. We screened the database stored in the Catholic Hematopoietic Stem Cell Bank of Korea and sorted the most frequent homozygous HLA types of the South Korean population. Blood cells with the selected homozygous HLA types were obtained and transferred to the GMP facility in the Catholic Institute of Cell Therapy. Cells were reprogrammed to iPSCs inside the facility and went through several quality controls. As a result, a total of 13 homozygous GMP-grade iPSC lines were obtained in the facility. The generated iPSCs showed high pluripotency and normal karyotype after reprogramming. Five HLA-homozygous iPSCs had the type that was included in the top five most frequent HLA types. Homozygous HLA-iPSCs can open a new opportunity for further application of iPSCs in clinical research and therapy.Entities:
Keywords: bone marrow blood cell; cord blood mononuclear cells; good manufacturing practice; human leukocyte antigen; induced pluripotent stem cells; peripheral blood mononuclear cells; stem cell banking
Mesh:
Substances:
Year: 2017 PMID: 28941241 DOI: 10.1002/term.2578
Source DB: PubMed Journal: J Tissue Eng Regen Med ISSN: 1932-6254 Impact factor: 3.963